CANCER CENTER CALGB PARTICIPATION

癌症中心 CALGB 参与

• 批准号: 2896418
• 负责人: HYMAN MUSS
• 金额: $ 8.25万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-20 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2896418
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): The Vermont Cancer Center (VCC), an NCI designated Comprehensive Cancer Center, joined the CALGB in 1995. In that short time the VCC has made significant headway in becoming a major participant in CALGB activities. Eight VCC members have made major commitments to supporting CALGB efforts. Dr. Hyman Muss continues to be extremely active in CALGB and serves as the Co-Chair of the Working Group for the Elderly and the Vice Chair of the Breast Cancer Committee, in addition to chairing two CALGB protocols (8869 and 9670). Dr. Steven Grunberg, a member of the Clinical Economics Committee, is currently developing a clinical protocol that will compare cost with symptom control for antiemetics. Dr. David Krag is an active member of the Breast Core Committee and is helping CALBG develop a protocol for sentinel node staging for women with early stage breast cancer. Dr. Seth Harlow will assume Dr. Krag's role as member of the Surgery Committee. Dr. Donald Weaver participates extensively in pathology group activities and has a major interest in breast cancer. Drs. Michael Cooper, Barbara Grant, and Richard Branda have major interest in urologic cancer, leukemia and lymphoma, and nutrition and cancer, respectively, and have developed concepts for CALGB clinical investigations. The development of multidisciplinary, disease-site oriented, affinity groups within our Center has established major liaisons between laboratory and clinical scientists. This will strengthen our institutional commitment to the group and allow VCC members to develop innovative companion trials for the CALGB. Recently, Drs. Grant and Branda presented two concepts-one related to assessing the importance of folate status on chemotherapy toxicity in women with early breast cancer, and a second that utilizes a novel reporter gene (hprt) to monitor and possibly define women with early stage breast cancer who might be at high risk for developing secondary acute nonlymphocytic leukemia. Drs. Weaver and other VCC scientists are drafting a concept that will explore the role of erbB-2 associated signaling proteins as mediators of apoptosis for women with early stage breast cancer treated with anthracyclines (CALGB 8541). We anticipate a major increase in accrual in the next year. The Green Mountain Oncology Group (CCOP) selected the VCC as its research base beginning in April, 1997. In one month they have entered 10 patients on CALGB protocols. Two new faculty will join the VCC this summer who have major interests in genetics and high-dose therapy; it is anticipated they will be active in CALGB activities. Also, we are developing a major outreach program and expect to add several affiliates with interest in clinical trials. In addition, we have developed a high-dose chemotherapy autologous stem cell support program and expect to become a CALGB Transplant Center by the start of the next funding period.

描述（改编自申请人的摘要）：佛蒙特州癌症 NCI 指定的综合癌症中心 (VCC) 加入 1995 年 CALGB。在那短短的时间内，VCC 在以下方面取得了重大进展： 成为CALGB活动的主要参与者。 八位 VCC 成员有 做出了支持 CALGB 工作的重大承诺。 海曼·穆斯博士 继续在 CALGB 中非常活跃，并担任 CALGB 的联合主席 老年人工作组和乳腺癌副主席 委员会，此外还主持两项 CALGB 协议（8869 和 9670）。 博士。 Steven Grunberg，临床经济学委员会成员，目前 制定临床方案，将成本与症状控制进行比较 用于止吐药。 David Krag 博士是乳房核心组织的活跃成员 委员会并正在帮助 CALBG 开发前哨节点分期协议 对于患有早期乳腺癌的女性。 塞思·哈洛博士将接任博士。 Krag 作为手术委员会成员的角色。 唐纳德·韦弗博士 广泛参加病理学团体活动并有重大成就 对乳腺癌的兴趣。 博士。迈克尔·库珀、芭芭拉·格兰特和理查德 Branda 对泌尿系统癌症、白血病和淋巴瘤非常感兴趣，并且 分别为营养和癌症，并开发了 CALGB 的概念 临床研究。 多学科、疾病现场的发展 我们中心内有针对性的亲和团体已建立了主要联络人 实验室和临床科学家之间。 这将加强我们的 对团体的制度承诺并允许 VCC 成员发展 CALGB 的创新伴随试验。 最近，博士。格兰特和布兰达 提出了两个概念——一个与评估叶酸的重要性有关 早期乳腺癌女性化疗毒性的现状，以及 第二个利用新的报告基因（hprt）来监测并可能 定义可能处于高风险的早期乳腺癌女性 发展为继发性急性非淋巴细胞白血病。 博士。韦弗等 VCC 科学家正在起草一个概念，探索 erbB-2 的作用 相关信号蛋白作为早期女性细胞凋亡的介质 使用蒽环类药物治疗的乳腺癌阶段 (CALGB 8541)。 我们预计 明年的应计费用将大幅增加。 绿山肿瘤学 集团（CCOP）从1997年4月开始选择VCC作为其研究基地。 在一个月内，他们已经按照 CALGB 方案纳入了 10 名患者。 两个新 对遗传学有重大兴趣的教师将于今年夏天加入 VCC 和高剂量治疗；预计他们将活跃于 CALGB 活动。 此外，我们正在制定一项重大的外展计划，并期望 添加几个对临床试验感兴趣的附属机构。 此外，我们 开发了高剂量化疗自体干细胞支持计划 并期望在明年开始时成为 CALGB 移植中心 资助期限。